Dose selection for intracerebroventricular cerliponase alfa in children with CLN2 disease, translation from animal to human in a rare genetic disease von Hammon, Kevin, Hart, Greg, Vuillemenot, Brian R., Kennedy, Derek, Musson, Don, O’Neill, Charles A., Katz, Martin L., Henshaw, Joshua W.

Volltext

Sensitive method for the quantitative determination of gemfibrozil in dog plasma by liquid–liquid cartridge extraction and liquid chromatography–tandem mass spectrometry von Roadcap, Brad A., Musson, Don G., Rogers, J.Douglas, Zhao, Jamie J.

Volltext

Abstract CT221: The effect of food on the oral bioavailability of the novel PARP 1/2 inhibitor BMN 673 in healthy male subjects von Henshaw, Joshua, Zhou, Huiyu, Musson, Don, O'Neill, Charles, Stoltz, Randall, Dorr, Andrew

Volltext

Abstract B67: Correlation of pharmacokinetics (PK), pharmacodynamics (PD) and in vivo antitumor activity of BMN 673 in preclinical models von Feng, Ying, Shen, Yuqiao, Musson, Don, Zhou, Huiyu, Scholler, Oriane, Post, Leonard E.

Volltext

Abstract A220: Inhibition of PBMC PARP activity with the novel PARP 1/2 inhibitor BMN 673 in patients with advanced solid tumors von Henshaw, Joshua W., Zhou, Huiyu, Herriott, Ashleigh, Patterson, Miranda, Wang, Evelyn W., Musson, Don, de Bono, Johann, Mina, Lida A., Ramanathan, Ramesh K., O'Neill, Charles, Dorr, Andrew, Curtin, Nicola J.

Volltext